iCo Therapeutics Inc (CVE:ICO) shares fell 7.1% during mid-day trading on Monday . The stock traded as low as C$0.07 and last traded at C$0.07. 290,860 shares were traded during trading, a decline of 37% from the average session volume of 461,306 shares. The stock had previously closed at C$0.07.
The stock has a market capitalization of $7.66 million and a PE ratio of -3.25.
iCo Therapeutics Company Profile (CVE:ICO)
iCo Therapeutics Inc, a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections.
Further Reading: What is a Roth IRA?
Receive News & Ratings for iCo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.